News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astex Pharmaceuticals (ASTX) Announces Oral Presentation of SGI-110 Data at the Upcoming European Cancer Congress (ECCO-ESMO-ESTRO)


6/20/2013 8:47:43 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DUBLIN, Calif., June 20, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced that updated clinical data from the dose escalation part of a randomized phase 1/2 clinical trial of subcutaneous SGI-110, a novel hypomethylating agent, in patients with relapsed/refractory acute myelogenous leukemia (r/r AML) will be presented in an oral session during the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam, Netherlands September 27 - October 1, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES